Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the USFDA for the inspection conducted at the API Ahmedabad facility. The company had earlier received Post Application Action Letter from the USFDA for the same inspection confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent an inspection from December 14 to 22, 2023 and has been classified as Voluntary Action Indicated (VAI).
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1621.25 |
| Dr. Reddys Lab | 1328.10 |
| Cipla | 1300.65 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2282.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: